Affected person information seize and medical trial tech firm uMotif introduced Wednesday it had secured $25.5 million from a fund managed by Athyrium Capital Administration.
WHAT IT DOEs
uMotif makes software program for gathering affected person information for medical trials and analysis, together with decentralized research. Its choices embrace instruments for acquiring consent, for digital medical consequence assessments (eCOA), for digital patient-reported outcomes (ePRO) and eDiaries, and for capturing symptom info and wearable information.
WHAT IT’S FOR
The corporate will use the capital to scale and develop its platform and proceed its worldwide enlargement. uMotif stated it is at present utilized in 30 international locations, and is especially targeted on rising its group in North America, together with in gross sales, advertising and repair supply.
“We’re delighted to welcome Athyrium to assist our journey to be essentially the most patient-centric platform for analysis. I really consider that medical analysis should put sufferers first, delivering extra partaking analysis research. With this funding from Athyrium I am excited to develop our international capabilities to higher serve our sponsors, companions and – most significantly – the sufferers we assist participate in analysis,” CEO Steve Rosenberg stated in a press release.
Within the wake of the COVID-19 pandemic that pushed many researchers to adapt to decentralized trials, a variety of startups are elevating funds for medical trial know-how.
In April, Reify Well being raised $220 million in Collection D funding, boosting its valuation to almost $5 billion. It provides software program for examine websites and sponsors to help in recruiting, pre-screening and enrolling sufferers in medical trials. Reify additionally gives touring analysis employees and delivers provides to arrange websites.
One other firm that focuses on decentralized trials is Curebase, which just lately raised $40 million in Collection B funding. The startup’s instruments embrace an app to assist sufferers enroll, signal consent varieties and entry telehealth and residential visits.
DCT firm THREAD can be increasing its affected person engagement instruments. In April, it introduced it had acquired CureClick, a platform for recruiting trial members. In the meantime, YPrime, a cloud-based medical trial information administration software, revealed plans to purchase Tryl, a platform that gives assist to sufferers so they do not drop out of trials, in February.